Dosing has begun in a Phase 1 clinical trial of healthy volunteers to evaluate the safety and pharmacological properties of NEU-723, Neuron23’s oral investigational treatment for Parkinson’s disease. The small molecule candidate therapy is designed to
Researchers have discovered a new genetic link between platelets in the bloodstream and Parkinson’s disease, according to a large-scale genetic study that investigated associations between blood measures and neurological and psychiatric diseases. Variation in platelet
Levels of nerve cell pentraxin proteins found in the cerebrospinal fluid (CSF) surrounding the brain and spinal cord are associated with motor and cognitive decline in people with Parkinson’s disease and related conditions, a study
The world-first Phase 3 clinical trial testing the ability of ambroxol, a medicine used for decades to treat lung conditions, to slow Parkinson’s disease progression is expected to start in the next few months. Called
A clinical trial testing the impact of low doses of psilocybin, a naturally occurring psychedelic compound, on inflammatory activity in people with Parkinson’s disease is on track to be completed by the end of February. Sponsored